Table 2 Univariate and multivariate analysis of the association of NCKAP1 with survival and recurrence in patients with hepatocellular carcinoma

From: NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma

Variables

OS

RFS

Univariate

Multivariable analysis

Univariate

Multivariable analysis

P value

HR (95% CI)

P value

P value

HR (95% CI)

P value

Age (yr) (≤50 versus >50)

0.619

  

0.877

  

Gender (female versus male)

0.678

  

0.981

  

Hepatitis B surface Ag (negative versus positive)

0.796

  

0.713

  

Serum AFP (ng/mL) (<400 versus ≥400)

0.026

0.020

1.674 (1.085–2.581)

0.080

  

Tumor size (cm) (≤5 versus>5)

0.000

0.000

2.630 (1.620–4.268)

0.000

0.000

2.719 (1.641–4.504)

Tumor number (solitary versus multiple)

0.001

0.161

1.377 (0.880–2.153)

0.000

0.042

1.594 (1.017–2.498)

PVTT (no versus yes)

0.000

0.006

2.170 (1.252–3.762)

0.000

0.060

1.704 (0.978–2.967)

Microvascular invasion (no versus yes)

0.000

0.000

3.067 (1.896–4.960)

0.000

0.000

2.922 (1.793–4.761)

Liver cirrhosis (no versus yes)

0.047

0.021

0.596 (0.385–0.925)

0.110

  

Differentiation grade (I + II versus III + IV)

0.036

0.114

1.397 (0.922–2.116)

0.025

0.063

1.489 (0.978–-2.267)

NCKAP1 (negative versus positive)

0.020

0.049

0.645 (0.417–0.997)

0.041

0.234

0.766 (0.493–1.189)

  1. OS overall survival, RFS recurrence free survival, AFP alpha-fetoprotein, PVTT portal vein tumor thrombus, HR hazard ratio, CI confidence interval